Using immunohistochemistry and electron microscopy, researchers mapped a previously unrecognized, dense network of nerves inside human deep fascia — including free nerve endings responsible for both position sense and pain. The authors conclude fascia is a sensory tissue and a plausible source of the musculoskeletal pain that standard imaging can't explain.

Systematic review of 23 histological studies confirming deep fascia is richly innervated by both mechanoreceptors and CGRP/substance-P nociceptors — and that nociceptor density is significantly increased in pathological fascia. The more dysfunctional the tissue, the more pain-capable it becomes.

Review describing the fascial system as highly innervated, vascular, and hormonally responsive — a whole-body sensing layer that is "intimately interdependent" with the nervous system. Fascial dysregulation is proposed as an underlying factor across hypermobility, autonomic dysfunction, and acquired connective tissue conditions.

Consensus paper from the leading fascial anatomy groups integrating histological, mechanical, and clinical data into a unified definition of fascia as a single, continuous, biologically active system — the formal end of the "inert wrapping" model.

Comprehensive review of hyaluronic acid biology in fascia. Details how fasciacytes — hyaluronic-acid-producing cells inside fascia — keep the layers hydrated and mobile, and how altered hyaluronic acid drives densification, stiffness, and sensitization of the nerve endings embedded in the tissue.

Pictorial review of ultrasound imaging in fascial disorders across rheumatology, sports medicine, and chronic pain — documenting fascial thickening, hyperechoic change, loss of fluid separation between layers, and inflammatory involvement. The tissue that was invisible on X-ray and MRI is now measurable.

Validation of ultrasound-guided core needle biopsy as a reliable method for sampling deep fascia (91.9–96.2% accuracy). For the first time, fascial pathology can be studied directly in patients rather than cadavers.

Imaging study showing the fascia of patients with chronic non-specific low back pain is thicker and stiffer than in healthy controls — in-vivo evidence that the relevant tissue change in "unexplained" back pain is fascial, not muscular or spinal.

Combined quantitative sensory testing and spinal fMRI showing the central nervous system in fibromyalgia patients responds normally to abnormally amplified peripheral input — reframing central sensitization as a downstream consequence of persistent peripheral drive rather than a primary nervous-system disease.

Mechanistic review concluding that peripheral tissue abnormalities increase tonic nociceptive supply to the spinal cord, which results in central sensitization — placing the upstream driver in the tissue, not the brain.

The director of the NIH's National Center for Complementary and Integrative Health proposes a model in which restricted movement between fascial layers impairs proprioception and drives nociception in the densely innervated fascia around muscle — directly linking fascial restriction to chronic pain.

Review showing targeted injection into fascial planes produces durable relief in persistent post-surgical pain, neuropathic pain, musculoskeletal pain, and cancer-related pain. If numbing the fascia stops the pain, the fascia was generating it.

Case series in which ultrasound-guided hydro-dissection — injecting saline between stuck fascial layers — produced immediate and sustained relief in chronic cervical myofascial pain. Direct evidence that the pain source is layer-to-layer fascial restriction.

The original paper proposing that inflammation and dysfunction of fascia is the peripheral input that drives central sensitization in fibromyalgia, citing biopsy evidence of increased collagen and inflammatory mediators in the connective tissue of patients. The 2023 update integrates newer findings — including that fibromyalgia antibodies transfer pain behavior to mice — into a fascia-centered model.

First imaging study to reliably show fibromyalgia-related tissue change. In 34 women with fibromyalgia versus 34 controls, quantitative ultrasound found significantly altered muscle texture and increased echointensity — physical findings in a condition long described as having "nothing to see."

One of the two 2025 imaging studies that moved fibromyalgia from "invisible" to measurable.

Ultrasound and elastography in 89 newly diagnosed women found thinner skin and subcutaneous layers and a thicker, stiffer trapezius compared to controls. Tissue stiffness correlated with pain severity. The authors propose these peripheral tissue changes drive sensitization.

The second 2025 imaging study. Stiffer tissue, more pain — measured, not theorized.

Scoping review of ~800 sources proposing fascial armoring — myofibroblast-driven tension, hyaluronan densification, and collagen remodeling — as the pathway connecting regional myofascial pain to the widespread pain of fibromyalgia.

Fascial cells carry sex-hormone receptors and change their collagen output according to estrogen levels. After menopause, the shift favors stiffer collagen and less elastic fiber. A physical basis for why fascia-driven pain conditions are dramatically more common in women, and why they cluster around hormonal transitions.

The same 2025 review documents how fascial thickening and densification increase mechanical load on sensory nerves inside and alongside the tissue, while neuroinflammatory signaling within fascia amplifies the resulting signal. Every peripheral nerve travels through fascia; when fascia densifies, the nerve is what gets squeezed.

Review framing fascia as a highly innervated regulatory layer contiguous with the peripheral nervous system. Fascial dysregulation is proposed as an under-recognized contributor to neuropathic symptoms, autonomic dysfunction, and small-fiber involvement.

The fascia itself is wired with small sensory fibers — the same class of fiber involved in burning, tingling, and small-fiber neuropathy. When the tissue around those fibers densifies, they misfire.

Animal study showing that after a peripheral nerve injury, hyaluronic acid concentration in fascia drops and collagen rises — not just at the injury site but in distant fascia as well. Nerve problems and fascial dehydration are linked systemically, and the change runs in the direction TrueForm® targets.

Systematic review of 39 studies finding that the proportion of people with X-ray-confirmed knee osteoarthritis who actually have pain ranges from 15% to 81%. Cartilage loss and pain are only loosely related. Something other than cartilage is generating most of the symptom.

Cartilage has no nerve supply. It can't hurt. This is the study that opens the question of what does.

Superficial fascia was the second most innervated tissue after skin (33 nerves/cm²) and deep fascia carried a rich small-fiber network, while the joint capsule itself was sparsely innervated. The authors identify fascia, not the capsule, as a key driver of persistent pain around an arthritic or replaced hip.

Translational review confirming oral hyaluronic acid supplementation reduces WOMAC pain, stiffness, and function scores in osteoarthritis patients without affecting safety markers — the most current synthesis of the human evidence.

Double-blind RCT in 156 knee OA patients: 100 mg/day of standardized pine bark extract reduced global WOMAC score by 56% versus 9.6% on placebo, tripled treadmill walking distance, and cut pain-medication use by 58%.

Ingredient: Pine Bark Extract

Systematic review of 11 studies (597 patients) finding 9 of 11 showed significant improvement in pain, function, and stiffness with oral hyaluronic acid. Two trials measured inflammatory cytokines and found them reduced. Authors conclude oral HA is safe and effective.

Ingredient: Hyaluronic Acid

Placebo-controlled trial in 31 adults: 12 weeks of oral high-molecular-weight sodium hyaluronate significantly reduced pain, stiffness, and discomfort scores versus placebo — benefit in non-arthritic joints, supporting a tissue-level rather than cartilage-level effect.

Ingredient: Hyaluronic Acid

Review confirming orally ingested hyaluronic acid is absorbed, distributes to connective tissue, and reduces pain and stiffness in human trials without affecting blood or urine safety markers.

Ingredient: Hyaluronic Acid

12-week supplementation study in 20 post-menopausal women with tissue biopsies before and after. Pine bark extract significantly increased hydration and elasticity, accompanied by a 44% rise in expression of hyaluronic acid synthase-1 — the enzyme the body uses to make its own hyaluronic acid — and a 29–41% rise in collagen type I gene expression.

This is why pine bark sits in the Rehydrate group: it doesn't just add hyaluronic acid, it turns up the body's own production.

Ingredient: Pine Bark Extract

Review documenting that grape seed proanthocyanidins induce TIMP-1 and reduce matrix metalloproteinase expression — the enzymes that degrade collagen and elastin — while cross-linking and stabilizing collagen fibers directly.

Ingredient: Grape Seed Extract · Pine Bark Extract

Umbrella review confirming silicon stimulates collagen production and that declining silicon in connective tissue tracks with declining collagen content. The mechanistic basis for bioavailable silica in a fascia formula.

Ingredient: Bamboo Extract (Silica)

Narrative review of 8 human studies concluding silicon supplementation improves collagen turnover markers and supports collagen cross-linking.

Ingredient: Bamboo Extract (Silica)

Manganese activates the glycosyltransferases and prolidase required to synthesize proteoglycans and collagen — the structural and water-binding components of fascia. Deficiency impairs connective tissue formation.

Ingredient: Manganese

Review of human evidence that boron improves the body's use of magnesium and vitamin D, reduces inflammatory markers including hs-CRP and TNF-α, and supports bone and connective tissue health.

Ingredient: Boron

Comprehensive review of serrapeptase's documented actions — hydrolysis of fibrin and inflammatory protein debris, COX modulation, and cytokine reduction. The enzyme acts on exactly the substrate that accumulates when fascia densifies.

Ingredient: Serrapeptase

Randomized controlled trial in 133 patients confirming serrapeptase reduced post-procedural swelling and restricted movement versus placebo — direct evidence of activity in soft connective tissue.

Ingredient: Serrapeptase

Prospective comparative study in 76 ankle-sprain patients: serrapeptase was superior to paracetamol in reducing soft-tissue edema at days 3 and 10.

Ingredient: Serrapeptase

Meta-analysis of 7 randomized trials (545 patients) finding Boswellia significantly reduced pain and stiffness and improved function versus controls. Authors conclude 4+ weeks of use is effective and safe.

Ingredient: Boswellia Extract

Three-arm RCT in 105 patients: standardized Boswellia extract significantly improved pain, stiffness, and walking distance, with measurable benefit by day 5 and reductions in inflammatory markers.

Ingredient: Boswellia Extract · industry-sponsored

PRISMA systematic review concluding gotu kola enhances connective tissue healing via stimulated type I collagen synthesis, increased growth-factor signaling, and reduced inflammatory cytokines.

Ingredient: Gotu Kola Extract

Review of asiaticoside, madecassoside, asiatic acid, and madecassic acid — documenting direct effects on collagen synthesis, fibroblast activity, inflammation reduction, and antioxidant protection.

Ingredient: Gotu Kola Extract

Annual peer-reviewed synthesis of fibromyalgia research documenting low-grade peripheral inflammation and tissue-level abnormalities as active areas of investigation — the field shifting from "purely central" toward an integrated peripheral-plus-central understanding.